H. Lundbeck A/S (HLBBF)

Market Cap	6.49B
Revenue (ttm)	3.78B
Net Income (ttm)	598.38M
Shares Out	n/a
EPS (ttm)	0.60
PE Ratio	10.85
Forward PE	7.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	1,230
Open	6.83
Previous Close	n/a
Day's Range	6.83 - 6.83
52-Week Range	4.42 - 7.55
Beta	0.38
RSI	54.78
Earnings Date	Feb 4, 2026

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 5,707
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLBBF

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial numbers in DKK